News

• Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report

  August 25, 2023

• Aclarion Announces New Commercial Engagement with The Imaging Center, Grand Rapids, MI

  June 14, 2023

• Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting

  June 8, 2023

• Aclarion Announces New Engagement with The London Clinic and London Spine Clinic

  May 30, 2023

• Aclarion's Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD

  May 23, 2023

• Aclarion, Inc. Announces Delayed 10-Q Filing

  May 23, 2023

• Aclarion Announces Non-Convertible Debt Financing to Achieve Three Critical Catalysts

  May 19, 2023

• Aclarion Appoints Nicholas Theodore, MD as Principal Investigator for CLARITY Post-Market Trial Evaluating Nociscan in the Diagnosis and Treatment of Chronic Low Back Pain

  May 2, 2023

• Aclarion to Host Thought Leadership Symposium at SPINEWEEK 2023

  April 28, 2023

• Aclarion Announces Publication of 2YR Outcomes in Groundbreaking Clinical Trial

  April 24, 2023